|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:activities
|
complement inhibition
|
|
gptkbp:approves
|
gptkb:2007
gptkb:European_Medicines_Agency
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:average_temperature
|
2 to 8 ° C
|
|
gptkbp:class
|
gptkb:drug
biologic
|
|
gptkbp:clinical_trial
|
Phase III
ongoing studies
long-term treatment
neuromuscular disorders
rare blood disorders
|
|
gptkbp:competitors
|
other complement inhibitors
|
|
gptkbp:contraindication
|
hypersensitivity to eculizumab
|
|
gptkbp:developed_by
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:dosage_form
|
injectable
600 mg
|
|
gptkbp:education
|
provided by manufacturer
|
|
gptkbp:effective_date
|
gptkb:2007
|
|
gptkbp:formulation
|
solution for infusion
|
|
gptkbp:frequency
|
every 2 weeks
every 4 weeks after initial doses
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Soliris
|
|
gptkbp:indication
|
gptkb:psychologist
gptkb:generalized_myasthenia_gravis
gptkb:paroxysmal_nocturnal_hemoglobinuria
chronic kidney disease
blood disorders
atypical hemolytic uremic syndrome
|
|
gptkbp:ingredients
|
gptkb:eculizumab
C_6484 H_10000 N_1716 O_2000 S_46
|
|
gptkbp:invention
|
2025
|
|
gptkbp:is_used_for
|
treatment of paroxysmal nocturnal hemoglobinuria
treatment of atypical hemolytic uremic syndrome
treatment of generalized myasthenia gravis
|
|
gptkbp:maintenance
|
900 mg
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:manufacturer
|
gptkb:Alexion_Pharmaceuticals,_Inc.
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
brand name Soliris
|
|
gptkbp:packaging
|
vial
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_access_to
|
available for patients
|
|
gptkbp:provides_information_on
|
gptkb:European_Hematology_Association
gptkb:American_Society_of_Hematology
gptkb:Kidney_Disease:_Improving_Global_Outcomes
gptkb:Myasthenia_Gravis_Foundation_of_America
included in treatment protocols
|
|
gptkbp:publishes
|
numerous studies
|
|
gptkbp:research_areas
|
neurology
autoimmune diseases
hematology
complement system
|
|
gptkbp:research_focus
|
autoimmune diseases
complement system
hemolytic disorders
|
|
gptkbp:safety_features
|
post-marketing surveillance
|
|
gptkbp:sales
|
increasing
|
|
gptkbp:scholarships
|
gptkb:stock_market_index
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
gptkb:fandom
headache
nausea
hypertension
sepsis
thrombosis
increased risk of infections
infusion reactions
serious infections
meningococcal infections
|
|
gptkbp:storage
|
2 to 8 degrees Celsius
|
|
gptkbp:type_of_insurance
|
varies by plan
|
|
gptkbp:weight
|
148,000 Da
|
|
gptkbp:bfsParent
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
4
|